Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling

BACKGROUND: Experimental uremic cardiomyopathy causes cardiac fibrosis and is causally related to the increased circulating levels of the cardiotonic steroid, marinobufagenin (MBG), which signals through Na/K‐ATPase. Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: Haller, Steven T., Yan, Yanling, Drummond, Christopher A., Xie, Joe, Tian, Jiang, Kennedy, David J., Shilova, Victoria Y., Xie, Zijian, Liu, Jiang, Cooper, Christopher J., Malhotra, Deepak, Shapiro, Joseph I., Fedorova, Olga V., Bagrov, Alexei Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5121507/
https://ncbi.nlm.nih.gov/pubmed/27694325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.004106
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi